A5042838792- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- MicroRNA in disease regulation
- Neuroscience and Neuropharmacology Research
- Pharmacological Effects and Assays
- Cancer Genomics and Diagnostics
- Classical Antiquity Studies
- Classical Philosophy and Thought
- Mast cells and histamine
- Immune cells in cancer
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Amino Acid Enzymes and Metabolism
- Polyamine Metabolism and Applications
- Receptor Mechanisms and Signaling
- Sport and Mega-Event Impacts
- Virus-based gene therapy research
- Cancer-related Molecular Pathways
Aziende Socio Sanitarie Territoriali di Lecco
2023
Fondazione IRCCS Istituto Neurologico Carlo Besta
2015-2019
Istituti di Ricovero e Cura a Carattere Scientifico
2018
Azienda Regionale Emergenza Urgenza
2016
Regione Lombardia
2016
The heterogeneous expression of tumor-associated antigens limits the efficacy chimeric antigen receptor (CAR)-redirected T cells (CAR-Ts) for treatment glioblastoma (GBM). We have found that chondroitin sulfate proteoglycan 4 (CSPG4) is highly expressed in 67% GBM specimens with limited heterogeneity. CSPG4 also on primary GBM-derived cells, grown vitro as neurospheres (GBM-NS), which recapitulate histopathology and molecular characteristics GBM. CSPG4.CAR-Ts efficiently controlled growth...
The R132H mutation of cytosolic isocitrate dehydrogenase (IDH1) is present in the majority low grade gliomas. Immunotherapy these tumors has an interesting, still unexploited, therapeutic potential, as they are less immunosuppressive than glioblastomas. Using site-directed mutagenesis we introduced into murine glioma cell line GL261, creating mIDH1-GL261. Presence was confirmed by immunoblotting and production oncometabolite 2-hydroxyglutarate (2HG), demonstrated mass spectrometry (LC-MS/MS)...
In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated dendritic cell (DC) immunotherapy associated to standard radiochemotherapy temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections mature DC loaded autologous GBM lysate administered before TMZ, while 4 performed during According Simon design, proceed the second stage progression-free survival (PFS) 12 months after surgery was expected in at least 8 cases enrolled stage....
In glioma patients, high levels of glutamate can cause brain edema and seizures. GLAST, a glutamate–aspartate transporter expressed by astrocytes with role in uptake, is highly on the plasma membrane glioblastoma (GBM) cells, its expression significantly correlates shortened patient survival. Here, it was demonstrated that inhibition GLAST limited progression invasion GBM xenografts. Magnetic resonance spectroscopy used to measure GLAST‐expressing gliomas showing these tumors exhibit...
The efficacy of dendritic cell (DC) immunotherapy as a single therapeutic modality for the treatment glioblastoma (GBM) patients remains limited. In this study, we evaluated in with GBM recurrence immune-mediated effects DC loaded autologous tumor lysate combined temozolomide (TMZ) or tetanus toxoid (TT).In phase I-II clinical study DENDR2, 12 were treated 5 vaccinations dose-dense TMZ. Subsequently, eight patients, here defined Variant (V)-DENDR2, vaccine site was preconditioned TT 24 hours...
Abstract In glioma patients, high levels of glutamate can cause brain edema and seizures. GLAST, a glutamate-aspartate transporter expressed by astrocytes with role in uptake, is highly on the plasma membrane glioblastoma (GBM) cells, its expression significantly correlates shortened patient survival. Here, it was demonstrated that inhibition GLAST limited progression invasion GBM xenografts. Magnetic resonance spectroscopy used to measure GLAST-expressing gliomas showing these tumors...
e14053 Background: Recurrent glioblastoma (GBM) are highly aggressive tumors allowing 6-8 month survival. Recent data suggested that tetanus/ diphtheria toxoid (Td) preconditioning could increase dendritic cells (DC) motility and efficacy of vaccination in newly diagnosed patients (Mitchell et al, 2015). Methods: Here we evaluated the possible benefits immunotherapy with mature DC loaded autologous tumor lysate 8 recurrent GBM, who received 24 hours before ipsilateral vaccine site...